ClinicalTrials.gg
CompletedNCT05913713Updated Sep 25, 2026

HIIT Following Breast Cancer Chemotherapy

An interventional study of 12-week Intervention Period and 12-week Observation Period in Breast Cancer, sponsored by University of Florida. Completed at 1 site in United States. Open to female participants aged 18 Years to 85 Years. Per ClinicalTrials.gov, last updated 2026-09-25.

Sponsored by University of Florida · Not applicable, Interventional, and Prevention

How we know

Updated Sep 25, 2026Now CompletedStudy documents posted+3 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
37
Allocation
Randomized
Ages
18 Years to 85 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 22 studies in Breast Neoplasms by University of Florida — 9 open to participants now, 10 under way, none of them phase 3. Breast Neoplasms · University of Florida.

Enrollment
7th of 18
37 · median 28
Started
2024
with 4 others
No phase
14 of 22
5 open now
Registered
16th of 22
by date

Among the 22 studies in Breast Neoplasms by University of Florida, this one is the 7th largest by enrollment of the 18 interventional ones that give a count, is one of 5 that started in 2024, is one of 14 with no phase, and was the 16th registered.

Breast Neoplasms

14,855 studies on the registry are indexed under Breast Neoplasms; 3,321 are open to participants now.

Browse Breast Neoplasms studies →

Open to participants now

9 of the 22 studies in Breast Neoplasms by University of Florida are open now, in 1 country. Recruiting first, the newest first:

4 more — sign in →

By country, each count listing its studies:

All 9 open studies →

Where they have run

Who these studies take

Of the 2,403 Breast Neoplasms studies recruiting now, 1,574 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 215 take healthy volunteers.

This study: 18 Years to 85 Years · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 22 studies in Breast Neoplasms by University of Florida, or all of them as a file.
02

Study summary

Chemotherapy is an effective breast cancer treatment, which helped to increase the 5-year survival rate to approximately 95%. However, breast cancer survivors have a higher risk of cardiovascular disease (CVD) due to chemotherapy than adults without cancer. Cardiovascular rehabilitation can be an effective strategy to decrease the incidence of CVD and its risk factors in this population. The proposed study may help to examine the effect and durability of a novel high-intensity interval training compared to moderate-intensity continuous training on cardiovascular rehabilitation in breast cancer survivors.

03

Conditions studied

  • Breast Cancer

Browse trials for

04

Who can participate

Ages eligible
18 Years to 85 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • female patients based on biological sex
  • 18 to 85 years of age
  • diagnosis of primary, invasive, non-, stages I-III breast cancer
  • completed chemotherapy for breast cancer (anthracycline, alkylating agent and/or taxane) more than 6 months but less than 18 months prior to study enrollment. endocrine therapy for breast cancer (e.g., ovarian suppression, SERMs, SERDs, AIs), CDK4/6 inhibitors, PARP inhibitors, targeted agents, immunotherapy, and bisphosphonates are allowed within 6 months of study enrollment and during study participation
  • absence of to exercise or to participate in study
  • study clinician approval

Exclusion criteria

Exclusion Criteria:

  • do not meet inclusion criteria
  • scheduled to receive surgery or radiation therapy during the intervention period
  • any relevant cardiovascular diseases (stroke, heart failure, myocardial ischemia during maximal graded exercise test, myocardial infarction, angina pectoris, coronary artery bypass surgery or angioplasty or coronary stent)
  • lymphedema stage ≥2 prior to study enrollment
  • are pregnant
  • current participation in other experimental interventions that may confound interpretation of study findings (e.g., dietary intervention for weight loss)
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
37 participants (actual)

Study arms

  • Experimental
    High Intensity Interval Training (HIIT)

    Supervised home-based high-intensity interval training will be performed on an all-extremity stationary cycle 3 days/week for 12 weeks.

    Behavioral: 12-week Intervention Period · Behavioral: 12-week Observation Period

  • Experimental
    Moderate Intensity Continuous Training (MICT)

    Supervised home-based moderate-intensity continuous training will be performed on an all-extremity stationary cycle 3 days/week for 12 weeks.

    Behavioral: 12-week Intervention Period · Behavioral: 12-week Observation Period

  • Other
    Usual Care (UC)

    Research participants will continue their habitual physical activity for the duration of the study. Once they complete the study, they will have the opportunity to perform supervised HIIT or MICT at home for 3 days/week for 12 weeks (research participants can choose either type of exercise).

    Behavioral: 12-week Intervention Period · Behavioral: 12-week Observation Period

Interventions

  • Behavioral12-week Intervention Period

    Research participants will be randomly assigned to either high-intensity interval training (HIIT), moderate-intensity continuous training (MICT), or the usual care (UC) group for a 12-week intervention period.

  • Behavioral12-week Observation Period

    After a 12-week intervention period (HIIT, MICT, or UC), research participants will have a 12-week observation period to assess the durability of two types of different exercises.

06

What researchers measure

Primary outcomes

  1. Change in brachial FMD

    Flow-mediated dilation (FMD) is an established non-invasive measure of endothelial function. Brachial artery FMD will be determined via ultrasonography in response to reactive hyperemia following 5-min forearm ischemia.

    Time frame: Baseline, Following a 12-week intervention period, Following a 12-week observation period

  2. Change in cardiac function (global longitudinal strain)

    Global longitudinal strain is a marker of acute subclinical cardiotoxicity and is recommended for monitoring cancer patients at risk of cancer therapy-related cardiac dysfunction.

    Time frame: Baseline, Following a 12-week intervention period, Following a 12-week observation period

  3. Percent completed vs. planned exercise frequency

    The investigators will collect information throughout the exercise intervention regarding % completed vs. planned exercise sessions/week.

    Time frame: Throughout the 12 weeks of supervised home-based exercise training

  4. Percent completed vs. planned exercise duration

    The investigators will collect information throughout the exercise intervention regarding % completed vs. planned exercise min/session.

    Time frame: Throughout the 12 weeks of supervised home-based exercise training

  5. Percent completed vs. planned exercise intensity

    The investigators will collect information throughout the exercise intervention regarding % completed vs. planned exercise intensity/session.

    Time frame: Throughout the 12 weeks of supervised home-based exercise training

  6. Number of participants who experience adverse events as defined by most recent CTCAE throughout the exercise intervention

    To evaluate safety plans are in place for determination and monitoring of adverse events according to the most recent National Cancer Institute Common Terminology Criteria for Adverse Events. Classification for seriousness, expectedness, severity and relationship to study intervention will be based on the NIH provided definitions.

    Time frame: Throughout the 12 weeks of supervised home-based exercise training

07

Study locations

1 site
  • Integrative Cardiovascular Physiology Laboratory, University of Florida
    Gainesville, Florida 32611, United States
08

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Mar 2024 to primary completion in May 2026, 26 months.

Of 2,673 non-industry interventional studies with no phase under Breast Neoplasms, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 66. This study's 26 months is below that.

Counting every sponsor, half of 2,783 studies reached it within 33 months; a quarter within 15 and three quarters within 66.

Since we started tracking on Sep 25, 2026, the dates moved once, on Sep 25, 2026: primary completion Dec 2026 → May 2026 and completion Dec 2026 → May 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jun 13, 2023
First posted
Jun 22, 2023
StartActual
Mar 7, 2024
Primary completionActual
May 20, 2026was Dec 2026
CompletionActual
May 20, 2026was Dec 2026
Last update
Sep 25, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Active, not recruiting→Completed
changed Sep 25, 2026
Primary completion
Dec 2026→May 20, 2026 (actual)
Sep 25, 2026
Study completion
Dec 2026→May 20, 2026 (actual)
Sep 25, 2026
Enrollment
158 (estimated)→37 (actual)
Sep 25, 2026
Documents
Sep 25, 2026
Show all 1 update
  1. Sep 25, 2026
    Active, not recruiting→Completed
    Documents Informed consent form ↗ posted
    Primary completion Dec 2026→May 20, 2026 (now actual)
    Study completion Dec 2026→May 20, 2026 (now actual)
    Enrollment 158 (estimated)→37 (actual)

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT05913713
Responsible party
Sponsor
First posted
Jun 22, 2023
Start date
Mar 7, 2024
Primary completion
May 20, 2026
Completion
May 20, 2026
Last update
Sep 25, 2026

Study contacts

Demetra Christou, PhD
principal investigator · University of Florida

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion